ʻO ka maʻi maʻi ʻaʻai ke kumu 2026: ʻO ka mālama ʻana a me ke kumukūʻai Kina - Nā halemai kokoke iaʻu 

Nā kumu maʻi ʻaʻai i ka makahiki 2026, ua hoʻokomo mua ʻia nā maʻi hepatitis B a me C, nā maʻi ate pili i ka waiʻona, nā maʻi momona momona ʻole (NAFLD), a me ka ʻike ʻana i nā aflatoxins. Ma Kina, ʻo ke kumu nui ka maʻi Hepatitis B maʻamau, e hoʻokele ana i kahi ʻāina lapaʻau kūʻokoʻa e hoʻohui i ka immunotherapy kiʻekiʻe, ka ʻoki ʻoki ʻana pololei, a me nā kumu kūʻai kūʻai ʻinikua aupuni. He mea koʻikoʻi ka hoʻomaopopo ʻana i kēia mau kumu no ka ʻike mua ʻana a me ke komo ʻana i nā lāʻau lapaʻau multidisciplinary hou loa i loaʻa i nā keʻena lapaʻau nui Kina.

ʻO nā kumu maʻi maʻi ate mua a me nā kumu pilikia ma 2026

Ua ulu ka etiology o ka hepatocellular carcinoma (HCC), akā naʻe, ʻo ka maʻi hepatitis viral ka mea hoʻokele koʻikoʻi ma ka honua a ma Asia. I ka makahiki 2026, hōʻike ʻia ka ʻae ʻana o ka lāʻau lapaʻau i kahi paradigm neʻe i kahi e piʻi wikiwiki ai nā mea metabolic me nā kumu maʻi maʻamau.

ʻO ka Hepatitis Viral Chronic: Ke alakaʻi mau

ʻO ka maʻi maʻi maʻi me ka maʻi Hepatitis B (HBV) ka mea koʻikoʻi nui loa no ka maʻi maʻi ate ma Kina. ʻAʻole like me nā ʻāina Komohana kahi i ʻoi aku ka nui o ka Hepatitis C a i ʻole ka waiʻona, ʻo ka HBV ka helu no ka hapa nui o nā hihia ma ka ʻāina. Hoʻopili ʻia ka maʻi i loko o ka genome host, e hoʻoulu ai i ka mumū mau a me ka cirrhosis, ka mea e alakaʻi ai i ka hoʻololi kino.

• Hepatitis B: He kuleana no ka 70-80% o nā hihia HCC ma Kina. ʻO ka hoʻouna pololei ʻana mai ka makuahine a i ke keiki ke lilo nei i kumu mōʻaukala, ʻoiai ua hōʻemi nā papahana o ka lāʻau lapaʻau i nā maʻi hou i nā hanauna ʻōpio.
• Hepatitis C: ʻOiai ka liʻiliʻi ma mua o ka HBV ma Kina, he kumu koʻikoʻi ia. Ua hoʻomaikaʻi ʻo Direct-acting antivirals (DAAs) i ka nui o ka mālama ʻana, akā mau ka poʻe maʻi me ka cirrhosis paʻa i ka pilikia ma hope o ka hoʻomaʻemaʻe viral.

Hōʻike nā alakaʻi hou i ka viremia haʻahaʻa haʻahaʻa i nā poʻe maʻi i mālama ʻia me nā analogues nucleos (t)ide hiki ke loaʻa i kahi pilikia. Hōʻike nā haʻawina i paʻi ʻia i ka makahiki 2026 e hiki i nā mea maʻi ma ka lāʻau antiviral mua ke loaʻa i ka viremia haʻahaʻa haʻahaʻa, pono e nānā makaʻala e pale i ka piʻi ʻana i ka maʻi kanesa.

ʻO ka Metabolic Dysfunction a me NAFLD

ʻO kahi kumu ulu wikiwiki o ka maʻi ate ma 2026 ʻo ia ka Non-Alcoholic Fatty Liver Disease (NAFLD), i kapa ʻia i kēia manawa ʻo Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Ke hoʻololi nei ka nohona ma waena o Kina, ua piʻi ka nui o ka momona a me ka maʻi diabetes type 2.

Ke hana nei kēia hoʻololi metabolic i kahi heluna kanaka hou o nā poʻe maʻi maʻi ʻaʻai ʻaʻole i loaʻa i ka maʻi hepatitis viral. Hoʻopili ka mīkini i ka ʻeha haʻahaʻa haʻahaʻa a me ke kaumaha oxidative i loko o nā waihona momona o ke ake. Hōʻike kēia ʻano i nā ʻano honua akā ke wikiwiki nei i ka heluna kanaka Kina ma muli o ka hoʻololi ʻana i ka meaʻai a me ka noho ʻana.

ʻO ka maʻi ate pili i ka waiʻona a me nā Aflatoxins

Ke hoʻomau nei ka inu ʻana i ka waiʻona i mea kōkua nui. Hana like ka waiʻona me ka maʻi hepatitis viral, e hoʻonui nui i ka pilikia o ka hoʻomohala ʻana i ka HCC. Ke loaʻa ka maʻi maʻi i ka HBV mau a me ka hoʻohana ʻana i ka waiʻona nui, piʻi nui ka nui o ka ulu ʻana o ka maʻi maʻi i ka hoʻohālikelike ʻia me ka loaʻa ʻana o nā mea pilikia wale nō.

Eia kekahi, ʻo ka ʻike ʻana i ka meaʻai i nā aflatoxins, nā mea ʻawaʻawa i hana ʻia e nā ʻōpala i mālama pono ʻole ʻia i nā kīʻaha a me nā nati, he mea hopohopo i kekahi mau wahi. ʻO Aflatoxin B1 kahi mea make kino ikaika e hoʻololi ai i nā ʻano hoʻololi kikoʻī i ka TP53 tumor suppressor gene. ʻOiai ua hoʻomaikaʻi ʻia nā hoʻoponopono palekana meaʻai, ʻo kēia kumu kaiapuni ke kōkua mau nei i ke kaumaha holoʻokoʻa o nā maʻi ma nā kuaʻāina.

ʻO Kina 2026 Hoʻomaʻamaʻa Landscape a me nā alakaʻi

Ua puka mai ʻo Kina ma ke ʻano he alakaʻi honua i ka noiʻi ʻana i ka maʻi maʻi ate a me ka hana hou ʻana. ʻO ka hoʻokuʻu ʻana o ka Nā Papa kuhikuhi no ka ʻike ʻana i ka maʻi maʻi ate ma mua (2026 Edition) hōʻailona i kahi kūlana koʻikoʻi. Hoʻohui kēia mau alakaʻi i nā hōʻike kiʻekiʻe mai nā hoʻokolohua lapaʻau alakaʻi ʻia e Kina, e hāʻawi ana i kahi "National Solution" i hoʻohālikelike ʻia i ka epidemiology kūikawā o ka ʻāina.

Nā Kūlana Kūlana Hou (2026 Edition)

Hoʻokuʻu ʻia i ka hoʻomaka ʻana o ka makahiki 2026, ʻo nā alakaʻi alakaʻi aupuni i hoʻopaʻa ʻia i nā hana e pili ana i nā hōʻike i hoʻokumu ʻia i ka ʻikepili kūloko. No nā makahiki he ʻumi, ua ulu kēia mau alakaʻi e hōʻike i nā hiʻohiʻona kūʻokoʻa o nā poʻe maʻi Kina, ka mea e hōʻike pinepine nei me nā pae maʻi ʻoi aʻe a me ka maʻi HBV.

Hoʻohui pū ʻia ka mana 2026 i nā hopena noiʻi lapaʻau kiʻekiʻe kiʻekiʻe, me nā ʻike kumu i paʻi ʻia ma nā puke pai honua e nā loea Kina. ʻO kēia ka mea e hōʻoia ai ʻaʻole i hoʻololi wale ʻia nā ʻōlelo aʻoaʻo lapaʻau i nā protocols Western akā ua hoʻopaʻa ʻia no nā ʻano genetic a me nā mea kaiapuni. Hoʻoikaika nā alakaʻi i ke kumu o ka hoʻokele "hui multidisciplinary" (MDT) ma ke ʻano o ka mālama mālama.

Hoʻohui ʻia o ka Immunotherapy a me ka Therapy Targeted

Ua hoʻololi ʻia ka mālama ʻana i ka maʻi maʻi ate maʻamau. ʻO ka 2026 Barcelona Clinic Liver Cancer (BCLC) hōʻano hou i ka ʻōnaehana, i unuhi ʻia e nā alakaʻi alakaʻi Kina, e hoʻopaʻa i ke kūlana o nā immuno-combination therapies ma ke ʻano he laina mua no ka maʻi Stage C.

• Kūlana Lālani ʻEkahi: ʻO ka hui pū ʻana o nā mea hoʻopaʻapaʻa hoʻopaʻa kino (e like me PD-1 monoclonal antibodies) me tyrosine kinase inhibitors (e like me sorafenib a i ʻole lenvatinib) i kēia manawa ke kūlana gula.
• Nā hoʻoponopono kikoʻī: Kākoʻo ka ʻikepili lapaʻau i ka hoʻohana ʻana i ka PD-1 inhibitors i hui pū ʻia me lenvatinib a i ʻole sorafenib, e hōʻike ana i ke ola holoʻokoʻa kiʻekiʻe ma mua o ka monotherapy.

ʻO ka noiʻi i hōʻike ʻia i ka hoʻomaka ʻana o 2026 e hōʻike ana i ka maikaʻi o kēia mau hui pū ʻana i nā mea maʻi me ka hana o ke akepaʻa Child-Pugh B, kahi hui i manaʻo ʻia he palupalu loa no ka ʻōnaehana systemic aggressive. Hāʻawi kēia hoʻonui ʻana i ka pono lapaʻau i ka manaʻolana i ka lehulehu o ka poʻe maʻi.

ʻO ka Neoadjuvant a me ka Conversion Therapy Consensus

ʻO kahi holomua nui i ka hepatology Kina ka hoʻomaʻamaʻa ʻana o nā neoadjuvant a me nā hoʻolālā hoʻololi hoʻololi. ʻO ka Ka Manaʻo Kūkākūkā Kina ma ka Neoadjuvant a me ka Hoʻololi ʻana no ka Hepatocellular Carcinoma (nā mea hou 2024/2026), i paʻi ʻia ma nā nūpepa kiʻekiʻe e like me Ka maʻi maʻi ʻaʻai, hāʻawi i kahi palapala alanui no ka hoʻohuli ʻana i nā maʻi ʻaʻole hiki ke hoʻololi ʻia i nā mea hiki ke hoʻihoʻi ʻia.

Hāʻawi ʻia ʻo 70-80% o nā mea maʻi Kina i ʻike ʻia i nā pae waena a i ʻole nā ​​pae holomua kahi i hiki ʻole ai ke ʻoki ʻana, he mea nui ka hoʻololi ʻana. Ke hoʻohana nei kēia ala i ka ʻōnaehana systemic e hōʻemi ai i nā maʻi maʻi, e ʻae ai i ka resection curative ma hope. Hoʻomaopopo ka ʻae ʻana i nā pae hoʻohālikelike no ke koho ʻana i nā mea maʻi, nā pōʻai lapaʻau, a me ka manawa o ka ʻoki ʻana, e hōʻemi ana i nā helu hoʻihoʻi i hiki i ka 70% i loko o ʻelima mau makahiki ma hope o ka hana.

Nā ʻenehana hoʻomaʻamaʻa kiʻekiʻe a me nā ʻenehana

ʻO ka ʻokiʻoki wale nō ke koho hoʻōla no ka maʻi maʻi ʻaʻai mua. Eia naʻe, ua hoʻonui ʻia ka wehewehe ʻana o ka "resectable" i ka loiloi preoperative maikaʻi aʻe a me nā hoʻoponopono hoʻohui. Ke hoʻohana nei nā kikowaena alakaʻi ma Kina i nā ʻenehana ʻokiʻoki e hoʻonui i nā hopena.

ʻO ka ʻoki ʻana a me ka hoʻololi ʻana i ke ake

ʻO nā keʻena olakino nui, e like me ka Hepatobiliary a me ka Pancreatic Center ma Beijing Tsinghua Changgung Hospital, hoʻohana i nā ala lāʻau kūpono. ʻO nā kauka lapaʻau e like me Academician Dong Jiahong alakaʻi i nā hui e hana i nā ʻokiʻoki paʻakikī me ka liʻiliʻi o ke kahe koko a me nā manawa hoʻōla wikiwiki.

Hoʻokaʻawale ʻia ka hoʻololi ʻana i ke ake no nā poʻe maʻi e hālāwai ana i nā koina kikoʻī (e like me ka Hangzhou Criteria a i ʻole UCSF criteria), i kekahi manawa ʻoi aku ka nui ma mua o nā koina Milan kuʻuna e hoʻokō i ka nui o nā hihia pili i ka HBV ma Kina. ʻO ka hoʻohui ʻana o ka antiviral prophylaxis post-transplant ua hōʻemi nui i ka helu hoʻi hou ʻana i nā mea loaʻa HBV-positive.

Radiotherapy hou: Lattice a me SBRT

Ua hoʻololi ʻia ka lāʻau lapaʻau mai kahi ana palliative a hiki i ke ʻano curative. ʻO ka 2026 BCLC hōʻano hou e pili ana i ka Stereotactic Body Radiation Therapy (SBRT) a me Transarterial Radioembolization (TARE) ma ke ʻano he koho lapaʻau radical no nā maʻi maʻi Stage 0/A ʻaʻole nā ​​moho no ka hōʻoki ʻana a i ʻole ablation.

Ke kau nei nā kānaka noiʻi Kina i ka "Lattice Radiotherapy" no nā maʻi maʻi ʻaʻole hiki ke hoʻopau ʻia (≥10 cm). Hāʻawi kēia ʻenehana i nā kiʻekiʻe kiʻekiʻe o ka radiation i nā node kikoʻī i loko o ka ʻōpū i ka wā e mālama ana i ka ʻiʻo olakino a puni. Hōʻike ʻia nā ʻikepili mua i hōʻike ʻia ma ka 2026 ASCO Annual Meeting i ka hoʻohiki ʻana i ka palekana a me ka maikaʻi o nā profiles i ka wā i hui pū ʻia me ka ʻōnaehana systemic.

Nā Kūlana Radiology Interventional

ʻO Transarterial Chemoembolization (TACE) ka pōhaku kihi no ka maʻi waena (BCLC B). Eia nō naʻe, mālama nā alakaʻi 2026 i ka hui maʻamau o TACE me ka ʻōnaehana systemic ma waho o nā hoʻokolohua lapaʻau, me ka ʻike ʻana ʻaʻole kākoʻo nā hōʻike o kēia manawa i kēia ala no nā pūʻulu āpau.

Hoʻohana ʻia nā lāʻau embolic hou a me nā peʻa lāʻau-eluting e hoʻomaikaʻi i ka pane ʻana i ka maʻi tumora. Eia kekahi, ʻo ka manaʻo o "ka neʻe ʻana o ka pae lapaʻau" hiki i nā kauka ke hoʻololi ikaika ma waena o TACE, systemic therapy, a me ka ʻoki ʻana e pili ana i ka pane ʻana o ka maʻi, e hōʻoia i ka loaʻa ʻana o nā mea maʻi i ka hana kūpono loa.

Ke ʻimi nei i nā halemai a me nā loea ma kahi kokoke iā ʻoe ma Kina

ʻO ka loaʻa ʻana o ka mālama kiʻekiʻe e pono ai ka ʻike i kahi o nā kikowaena o ka maikaʻi. Haʻaheo ʻo Kina i kekahi mau kikowaena hepatobiliary papa honua i lako me ka ʻenehana hou a me nā hui multidisciplinary.

Nā Kikowaena Hepatobiliary Kiʻekiʻe

ʻO ka Halemai ʻo Tsinghua Changgung ʻo Beijing: Alakaʻi ʻia e ke Academician Dong Jiahong, kaulana kēia kikowaena no nā ʻoki ʻoki paʻakikī a me ka hoʻololi ʻana o ke kino. Aia i loko o ka hui nā loea e like me Dr. Lu Qian a me Kauka Xiang Canhong, ka mea loea i nā ʻokiʻoki pololei a me ka hoʻokele multidisciplinary. Hāʻawi lākou i nā keʻena lapaʻau kūikawā no nā hihia paʻakikī, me ka poʻe me ka vascular invasion.

Ke Kula Nui ʻo Fudan Zhongshan Hospital (Shanghai): He hub no ka noiʻi ʻana i ka maʻi maʻi ate a me ka noi lapaʻau. Ma lalo o ke alakaʻi ʻana o nā loea e like me Professor Gao Qiang, he mea nui kēia haukapila i ka hoʻokumu ʻana i nā alakaʻi aupuni a me ka hoʻokō ʻana i ka hoʻoholo hoʻoholo CUSE hou. He alakaʻi ia i ka hoʻohui ʻana i ka radiology interventional me ka systemic therapy.

Halemai Zhongnan o ke Kulanui o Wuhan: ʻIke ʻia no kona holomua ʻana i ka radiotherapy a me ka chemoradiotherapy no nā iwi a me nā ʻiʻo palupalu a me nā maʻi maʻi hepatobiliary. ʻO kā lākou hoʻouna hou ʻana iā ASCO e hōʻike ana i nā mea hou i ka lattice radiotherapy a me nā haʻawina reprogramming metabolic.

Pehea e komo ai i ka mālama

ʻO ka hapa nui o nā haukapila kiʻekiʻe ma Kina e hana ma kahi ʻōnaehana koho. Hiki i nā poʻe maʻi ke hoʻopaʻa i nā kūkākūkā ma o nā moʻokāki WeChat o ka haukapila, nā polokalamu i hoʻolaʻa ʻia, a i ʻole nā ​​kelepona kelepona. No nā maʻi maʻi honua a i ʻole ka poʻe mai nā panalāʻau mamao, nui nā kikowaena e hāʻawi i nā kūkākūkā mua telemedicine e nānā i ke kiʻi a me ka pathology ma mua o ka huakaʻi.

• KaʻAnuʻu 1: E hōʻiliʻili i nā moʻolelo olakino a pau, me ka CT/MRI scans (ma DICOM CD), nā hōʻike maʻi maʻi, a me nā hopena hoʻāʻo koko (ʻoi aku ka AFP a me ka hana ate).
• KaʻAnuʻu 2: E hoʻokaʻaʻike i ka ʻoihana lapaʻau honua o ka haukapila a i ʻole e hoʻohana i ka platform digital official e kākau inoa no kahi loea i ka Hepatobiliary Surgery a i ʻole Hepatology.
• KaʻAnuʻu 3: E hele i ke keʻena ʻoihana Multidisciplinary Team (MDT) inā loaʻa. E hōʻoia kēia i ka loiloi ʻana o nā kauka lapaʻau, oncologists, a me radiologists i ka hihia e hoʻolālā i ka hoʻolālā maikaʻi loa.

Nā kumukūʻai lapaʻau a me ka uhi ʻinikua ma 2026

ʻO ke kumukūʻai o ka mālama ʻana i ka maʻi maʻi ate ma Kina he ʻano like ʻole ma muli o ke ʻano o ka maʻi, ke ʻano lapaʻau i koho ʻia, a me ka pae o ka haukapila. Eia nō naʻe, ʻo ka ʻōnaehana mālama ola olakino koʻikoʻi ua hoʻolilo i nā lāʻau lapaʻau kiʻekiʻe i hiki ke maʻalahi.

Hoʻokaʻawale i nā kumukūʻai lapaʻau

ʻO ka ʻoki ʻoki ʻana: ʻO ke kumukūʻai no ka hepatectomy maʻamau mai 40,000 a 80,000 RMB ($5,500 - $11,000 USD). Hiki ke kūʻai ʻia ma waena o 80,000 a me 120,000 RMB nā ʻokiʻoki paʻakikī e pili ana i ke kūkulu hou ʻana i nā ʻōpū a i ʻole ka laparoscopic/robotic approaches.

ʻO ka hoʻololi ʻana i ke akepaʻa: ʻO kēia ke koho kūʻai nui loa, maʻamau mai 400,000 a 600,000 RMB ($ 55,000 - $ 83,000 USD). Hoʻopili kēia i ke ʻoki ʻana, nā uku o ka loaʻa ʻana o ke kino, a me ka hoʻokipa mua. Hoʻohui ka lāʻau immunosuppressive lōʻihi i ke kumu kūʻai.

ʻO ka lāʻau lapaʻau: Ma mua o nā kūkākūkā hou ʻana, ua pāpā ʻia nā lāʻau lapaʻau a me nā immunotherapies. I ka makahiki 2026, ma muli o ka loaʻa ʻana o ka nui o ka lehulehu (VBP) a me ka hoʻokomo ʻana i ka National Reimbursement Drug List (NRDL), ua emi nui nā kumukūʻai. ʻO nā kumukūʻai o kēlā me kēia mahina no ka PD-1 inhibitors a me nā TKI hiki i kēia manawa ke haʻahaʻa e like me 2,000 a 5,000 RMB ($ 280 - $ 700 USD) no nā maʻi i hoʻopaʻa ʻia.

Nā Kulekele Hoʻihoʻi Inikua

Ua uhi ʻia ʻo China's Basic Medical Insurance (BMI) i kahi hapa nui o ka mālama ʻana i ka maʻi maʻi ate. ʻOi aku ka nui o ka uku hoʻopiʻi no nā koina maʻi maʻi ma nā halemai aupuni ma mua o 70% no nā limahana o ke kūlanakauhale a emi iki no nā kamaʻāina kuaʻāina, ma muli o ka ʻāina.

• Papa inoa Laau Laau Laau Lapaau Lahui (NRDL): Nui nā hui immunotherapy laina mua (e laʻa, camrelizumab, sintilimab i hui pū ʻia me apatinib a i ʻole rivoceranib) i kēia manawa e uku hou ʻia. ʻO kēia hoʻololi kulekele he mea hoʻololi pāʻani, e hiki ai i ka lehulehu ke loaʻa i ka lāʻau lapaʻau maʻamau.
• Inikua ma'i ko'iko'i: Hāʻawi nā papahana ʻinikua hoʻohui i ka uhi hou no nā hoʻolimalima olakino pōʻino, e hōʻemi hou ana i nā kumukūʻai waho o ka ʻeke no nā ʻohana.

No nā poʻe maʻi maʻi honua ʻole, e ʻoi aku ke kiʻekiʻe o nā kumukūʻai ke uku lākou i ke kumukūʻai papa inoa piha. Eia nō naʻe, ʻoiai ma ke kumukūʻai piha, ʻoi aku ka maikaʻi o ka mālama ʻana ma Kina i ka hoʻohālikelike ʻia me ka US a i ʻole ʻEulopa, me ka ʻole o ka hoʻololi ʻana i ka maikaʻi o ka mālama a i ʻole ke komo ʻana i nā lāʻau lapaʻau hou loa.

Ka Hoʻohālikelike Hoʻohālikelike o nā Kūlana Lapaʻau

ʻO ke koho ʻana i ka lāʻau lapaʻau kūpono e pili ana i ke ʻano o ka tumo, ka hana o ka ate, a me ke kūlana hana o ka mea maʻi. Hoʻohālikelike ka papa ma lalo nei i nā ʻano hana mua i loaʻa ma Kina i 2026.

ʻO ka CUSE hoʻoholo hoʻoholo

ʻO kahi holomua koʻikoʻi ma 2026 ʻo ia ka hoʻopaʻa ʻana i ka CUSE framework i ka hoʻoholo hoʻoholo maʻi. Manaʻo ʻia i nā alakaʻi BCLC hou a hoʻokūkū ʻia e nā poʻe loea Kina, neʻe kēia kükohu ma waho aʻe o nā algorithms paʻa i kahi ala hoʻomanawanui.

Ka Hoomaopopo ana i na Anana Eha

Hoʻolālā ka CUSE framework i ʻehā mau ʻāpana koʻikoʻi e alakaʻi i ka Pūʻulu Multidisciplinary (MDT):

• Paʻakikī: Hoʻomaopopo i ke ʻano multifactorial o ka maʻi, e noʻonoʻo ana i ka biology tumor, physiology ate, a me nā comorbidities i ka manawa like.
• ʻAʻole maopopo: Hoʻopuka i ka wānana fuzzy a me ke ʻano iterative o nā hōʻike olakino. Hāʻawi ia i ka maʻalahi i ka wā e puka mai ai ka ʻikepili hou i ka wā o ka mālama ʻana.
• Nā kumuhana: Hoʻomaopopo i nā ʻokoʻa o kēlā me kēia kanaka i ka ʻike ʻana o nā kauka a me nā maʻi i nā pilikia a me nā pōmaikaʻi. Hoʻohui ia i nā makemake a me nā waiwai o ka maʻi.
• Nā kumu noʻonoʻo: E noʻonoʻo i ka hopena noʻonoʻo, nā ʻike i hala, a me nā manaʻo pilikino o ka mea maʻi a me ka hui mālama.

ʻO kēia kaʻina hana e hōʻoiaʻiʻo ʻaʻole ʻoi aku ka maikaʻi o nā hoʻolālā lapaʻau akā hiki ke kūpono a ʻae ʻia i kēlā me kēia maʻi. He mea maikaʻi loa ia i nā hihia palena palena kahi e loaʻa ai nā koho lapaʻau he nui, e kōkua ana i ka hoʻokele ʻana i nā kālepa ma waena o ka huhū a me ka maikaʻi o ke ola.

Noiʻi hou a me nā kuhikuhi e hiki mai ana

Ke hāʻawi ikaika nei nā hui noiʻi Kina i ka ʻike honua o ka maʻi maʻi ate. ʻO nā haʻawina hou i hōʻike ʻia ma nā ʻaha kūkā nui e like me ASCO 2026 e hōʻike ana i kekahi mau ala hoʻohiki.

Metabolic Reprogramming a me Ferroptosis

Ke ʻike nei nā mea noiʻi pehea e hoʻololi ai ka metabolic i ka holomua o ka maʻi kanesa. Ua hōʻike ʻia nā haʻawina mai ka Halemai ʻo Wuhan Zhongnan e hiki i nā metabolites e like me alpha-ketoglutarate ke hoʻoulu i ka ferroptosis (iron-dependent cell death), e hoʻonui ai i ka naʻau o ka colorectal a me ka ate i ka radiation. Wehe kēia i nā puka no nā lāʻau lapaʻau hui e hoʻopunipuni i ka metabolism tumor e hoʻonui i ka pono o nā lāʻau kuʻuna.

ʻO nā maʻi maʻi oncolytic a me nā mea hou Immunotherapies

Ke kūkulu ʻia nei nā immunotherapies hou. Ke noiʻi nei nā hoʻokolohua lapaʻau i nā maʻi maʻi oncolytic (e like me OH2) i lawelawe pololei ʻia i loko o nā ʻōpū, a ukali ʻia e ka systemic immune checkpoint blockade. Hōʻike ka ʻikepili mua i kēia ala kaʻina hiki ke hoʻoulu i ka pane ʻana i ka immune anti-tumor, ʻoiai i nā maʻi "anu" i pane pinepine ʻole i ka immunotherapy wale nō.

Ka hoʻoponopono ʻana i nā metastases o ka ate colorectal

ʻOiai ʻo HCC ka manaʻo nui, ʻo ka piʻi ʻana o ka maʻi maʻi colorectal (CRC) ma Kina i lawe mai i ka nānā ʻana i ka Colorectal Liver Metastases (CRLM). Me ka lilo ʻana o CRC i ka lua o ka maʻi maʻi maʻamau ma Kina, koʻikoʻi nā hoʻolālā kūikawā no CRLM. Ke hōʻoia nei ka mālama ʻana o ka ʻāina a me ka hoʻokele holoʻokoʻa e hoʻolōʻihi i ke ola no kēia mau maʻi, me nā papa inoa e hōʻike ana ʻo ke ake ka wahi maʻamau o ka metastasis no CRC.

Nā nīnau i nīnau pinepine ʻia e pili ana i ka maʻi maʻi ate ma Kina

Hiki ke ho'ōla 'ia ka ma'i 'a'ai ma 2026?

ʻAe, hiki ke hoʻōla ʻia ka maʻi maʻi ʻaʻai mua ma o ka ʻoki ʻoki ʻana, ka hoʻololi ʻana i ke akepaʻa, a i ʻole ablation. No nā pae kiʻekiʻe, ʻoiai ʻaʻole maʻamau ka "ho'ōla", ʻo ka pahuhopu ka mana lōʻihi a me ka hoʻonui ola. ʻO ka hiki ʻana mai o nā lāʻau lapaʻau immuno-combination maikaʻi ua hoʻohuli i ka HCC kiʻekiʻe i kahi maʻi maʻi maʻi hiki ke mālama ʻia no nā maʻi he nui, me ka hoʻomaikaʻi nui ʻana i ka nui o ke ola ma waena o nā makahiki i hala.

ʻEhia ke kumukūʻai o ka mālama ʻana i ka maʻi maʻi ate ma Kina?

He ʻokoʻa nā kumukūʻai. He $6,000 USD paha ke kumukūʻai maʻamau, ʻoiai ʻoi aku ka paʻakikī o nā transplants ma mua o $80,000 USD. Eia nō naʻe, no nā kamaʻāina Kina me ka ʻinikua, ʻoi aku ka haʻahaʻa o nā lilo o waho ma muli o nā kulekele hoʻihoʻi. ʻO nā lāʻau lapaʻau kiʻekiʻe e like me ka PD-1 inhibitors hiki ke kūʻai aku i kēia manawa, e kūʻai ana i kahi mau haneli kālā i kēlā me kēia mahina ma hope o ka ʻinikua, e hiki ai ke loaʻa i ka lāʻau lapaʻau honua.

He aha nā kumu nui o ka maʻi maʻi ate ma Kina?

ʻO ke kumu nui ka maʻi Hepatitis B mau, ʻo ia ka helu no ka hapa nui o nā maʻi. ʻO nā kumu koʻikoʻi ʻē aʻe ʻo ia ka Hepatitis C, ka inu ʻawaʻawa nui, a me ka hoʻonui ʻia ʻana o ka maʻi ʻaʻai momona ʻole (NAFLD) i alakaʻi ʻia e ka momona a me ka maʻi diabetes. ʻO ka hoʻolaha ʻana o Aflatoxin he mea pilikia ma nā wahi kikoʻī.

Hiki iaʻu ke loaʻa ka lāʻau lapaʻau ma Kina ma ke ʻano he haole?

ʻOiaʻiʻo. ʻO nā haukapila nui e like me Beijing Tsinghua Changgung Hospital a me Fudan Zhongshan Hospital he mau keʻena honua e mālama ana i nā maʻi maʻi. Hāʻawi lākou i nā mea hoʻonohonoho ʻōlelo Pelekania, kōkua me nā visa, a me nā hoʻolālā lapaʻau kūpono. ʻOiai ʻokoʻa paha ka hoʻopiʻi ʻinikua, pili ka maikaʻi o ka mālama i nā kūlana honua, pinepine ma ka huina haʻahaʻa haʻahaʻa ma mua o nā ʻāina Komohana.

Ka hopena

ka hoomaopopo ana nā kumu maʻi maʻi ate ʻo ia ka ʻanuʻu mua i ka pale ʻana a me ka ʻike mua ʻana, ʻo ia hoʻi ma nā wahi pilikia nui e like me Kina kahi e loaʻa ai ka Hepatitis B. I ka makahiki 2026, ʻike ʻia ka ʻāina o ka mālama ʻana i ka maʻi maʻi ate ma Kina e ka wikiwiki o ka hana hou ʻana, nā hoʻoponopono alakaʻi koʻikoʻi, a me ka kūpaʻa ikaika i ka hiki ke loaʻa i nā lāʻau lapaʻau holomua. Mai ka hoʻohana ākea ʻana i nā regimens immuno-combination a hiki i ka hoʻomaʻemaʻe ʻana i nā ʻano hana ʻokiʻoki a me ka hoʻokō ʻana i nā ʻōnaehana hoʻoholo e pili ana i ka mea maʻi e like me CUSE, ke kau nei ʻo Kina i nā hōʻailona hou i ka mālama hepatobiliary.

ʻOi aku ka nui o nā koho ma mua o ka wā ma mua. Inā ma o ka hoʻomaʻamaʻa curative, radiotherapy pololei, a i ʻole nā ​​ʻōnaehana hoʻonui ola, ʻo ka hoʻohui ʻana o ka loea multidisciplinary e hōʻoia i ka loaʻa ʻana o kēlā me kēia mea maʻi i kahi hoʻolālā kūpono. Me ke kākoʻo o nā kulekele ʻinikua aupuni e hōʻemi ana i nā pale kālā, ʻoi aku ka maopopo a me ka manaʻolana o ke ala mai ka hōʻoia ʻana i ke ola. No ka poʻe e ʻimi nei i ka lapaʻau, hāʻawi nā hale papa honua a me nā hui loea ma Kina i kahi kukui o ka manaʻolana, e hui pū ana i ka ʻepekema ʻokiʻoki me ka mālama aloha e hakakā i kēia maʻi weliweli.